Date: 2017-10-24
Type of information: Private placement
Company: Immune Design (USA - MA)
Investors:
Amount: $86.6 million
Funding type: private placement
Planned used:
- Immune Design plans to use the net proceeds of the offering to fund its Phase 3 clinical trial for CMB305 in synovial sarcoma patients, continue to develop CA21, its next-generation prime-boost product candidate, and file an IND for its initial development, as well as for working capital and general corporate purposes.
Others:
- • On October 27, 2017, Immune Design completed an underwritten follow-on public offering, which resulted in the sale of 22,425,000 shares of common stock, inclusive of the full exercise by the underwriters of the 30-day option to purchase 2,925,000 additional shares, at a public offering price of $4.10 per share. Estimated net proceeds from the offering were $86.6 million after deducting underwriting discounts and commissions and estimated offering expenses of $5.4 million. Both new and existing investors participated in the offering.
- • On October 24, 2017, Immune Design announced the pricing of an underwritten public offering of 19,500,000 shares of its common stock at a price to the public of $4.10 per share. All of the shares of common stock are being offered by Immune Design. Proceeds to Immune Design from this offering are expected to be approximately $80.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on October 27, 2017, subject to customary closing conditions.
- • On October 23, 2017, Immune Design announced that it plans to offer and sell up to 16,000,000 shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Immune Design. The offering is subject to market conditions.
- Leerink Partners LLC, Cowen and Company, LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the offering. In connection with the offering, Immune Design intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.
Therapeutic area: Cancer - Oncology
Is general: Yes
